Asset profile
NanoLithium NP03
Small molecule
Evidence outlook · program status
Discontinued (2025-03-07), when the company ceased operations
NanoLithium NP03 was Medesis Pharma's buccal nanomicellar lithium for Alzheimer's disease; its phase 2 NanoLi-AD study (NCT05423522) completed and the company was seeking a licensing partner to fund phase 3. Medesis Pharma itself was placed in judicial liquidation by the Montpellier Commercial Court on 7 March 2025 after a safeguard procedure and a receivership, and its shares were suspended; the company's website no longer resolves. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 31 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| NanoLithium NP03: this drug | Phase 2 | Small molecule | GSK3-beta (lithium, nanoparticle delivery) | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| AR1001 | Phase 3 | Small molecule | PDE5 | ||
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | ||
| Blarcamesine | Phase 3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | ||
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | ||
| Cerebrolysin | Phase 3 | Peptide | Multi-target (ginsenoside) | ||
| GV1001 | Phase 3 | Peptide | Telomerase (hTERT) | ||
| Hydromethylthionine Mesylate | Phase 3 | Small molecule | Tau aggregation; Acetylcholine | ||
| Lemborexant (Dayvigo) | Phase 3 | Small molecule | Orexin receptor (repositioned) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.